News articles about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.6184401648648 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH (markets.businessinsider.com)
- Regeneron (REGN) and Alnylam (ALNY) Announce Pact to Discover New Treatments for NASH (streetinsider.com)
- Regeneron (REGN) and Alnylam (ALNY) Announce Pact to Discover New Treatments for NASH – StreetInsider.com (streetinsider.com)
- Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH) (finance.yahoo.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
Several analysts have issued reports on ALNY shares. BidaskClub lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. B. Riley reissued a “buy” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, December 11th. Goldman Sachs raised Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Piper Jaffray Companies reissued a “buy” rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a report on Sunday, January 7th. Finally, Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Friday, January 19th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $126.89.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm had revenue of $37.90 million for the quarter, compared to the consensus estimate of $19.31 million. During the same period in the previous year, the company posted ($1.32) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 116.6% on a year-over-year basis. equities analysts anticipate that Alnylam Pharmaceuticals will post -6.88 EPS for the current year.
In related news, VP Michael Mason sold 36,745 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Paul Schimmel sold 27,823 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $150.00, for a total value of $4,173,450.00. Following the sale, the director now owns 10,000 shares in the company, valued at $1,500,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 226,582 shares of company stock valued at $32,019,428. 4.30% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This article was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/22/alnylam-pharmaceuticals-alny-given-daily-media-sentiment-rating-of-0-19/1927081.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.